BD Canada's head office building in Mississauga, On, Canada_ By JHVEPhotoBecton, Dickinson and Company (BDX) develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. The global medical technology giant is expected to announce its fiscal third-quarter earnings for 2026 before the market opens on Thursday, Aug. 6. More News from BarchartFor the full year, analysts expect BDX to report EPS of $12.62, down 12.4% from $14.40 in fiscal 2025. BDX stock has underperformed the S&P 500 Index's ($SPX) 18.2% gains over the past 52 weeks, with shares up 9.9% during this period. Analysts' consensus opinion on BDX stock is reasonably bullish, with a "Moderate Buy" rating overall.